TABLE 1.
Demographic and Clinical Characteristics of the Study Population
| Variable | Children With Epilepsy (n, %) |
|---|---|
| Median age (years, (Q1, Q3)) | 8.50 (7.00, 11.00) |
| Gender | |
| Male | 125 (55.80%) |
| Female | 98 (43.75%) |
| Unknown | 1 (0.45%) |
| Median duration (years) (Q1, Q3) | 3.0 (2.0, 4.875) |
| Etiology | |
| Genetic | 17 (7.59%) |
| Structural | 10 (4.46%) |
| Metabolic | 0 (0.00%) |
| Immune | 2 (0.89%) |
| Infectious | 4 (1.79%) |
| Unknown | 191 (85.27%) |
| Seizure type | |
| Generalized epilepsy | 59 (25.34%) |
| Focal epilepsy | 140 (62.50%) |
| Unknown | 25 (11.16%) |
| Numbers of ASMs | |
| 0 | 8 (3.57%) |
| 1 | 175 (78.13%) |
| 2 | 36 (16.07%) |
| 3 | 5 (2.23%) |
| Vaccine type | |
| Inactivated vaccine | 224(100%) |
Abbreviation:
ASM = Antiseizure medication